Loading
Everything OnCo dates to 2029: 19 entries, 19 expected dates. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
19 dated entries in OnCo fall in 2029: 19 expected dates.
Of those, 16 to the day and 3 to the month. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
Dates a source states for something still to come: roadmap watch items, the readout calendar, company catalysts, and registry primary completion dates.
Watch item on the Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.
Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.
Watch item on the Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific anti...
Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...
Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...
Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...
Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...
Estimated primary completion date on ClinicalTrials.gov.
Estimated primary completion date on ClinicalTrials.gov.
Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.
Watch item on the Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific anti...
Estimated primary completion date on ClinicalTrials.gov.
Estimated primary completion date on ClinicalTrials.gov.
Estimated primary completion date on ClinicalTrials.gov.
Estimated primary completion date on ClinicalTrials.gov.
Estimated primary completion date on ClinicalTrials.gov.
Estimated primary completion date on ClinicalTrials.gov.